Tolerogenixx raises €11.6M Series A round
6 July 2023· Heidelberg, Germany· health, immunotherapy, biotech, b2b, deep_hardware
The funding will be used to successfully complete the company's Phase II program, specifically the TOL2 Phase IIb study in renal transplant patients, and to further develop its pipeline for autoimmune diseases.
Investors
LeadDB Speciality GmbH & Co. KG
Also participating
High-Tech GründerfondsKalodion Fond ICventureSNisusDr. Dr. DorowDr. Dr. FaklerBiotech Mountains BV
About Tolerogenixx
Stage
Series A
Headquarters
Heidelberg, Germany
Founded
2016
Team Size
6–20
Sectors
healthimmunotherapybiotechb2bdeep_hardware